Article ; Online: Biomimetic nanoplasmonic sensor for rapid evaluation of neutralizing SARS-CoV-2 monoclonal antibodies as antiviral therapy
Biosensors and Bioelectronics. 2023 Feb. 08, p.115137-
2023 , Page(s) 115137–
Abstract: Monoclonal antibody (mAb) therapy is one of the most promising immunotherapies that have shown the potential to prevent or neutralize the effects of COVID-19 in patients at very early stages, with a few formulations recently approved by the European and ... ...
| Abstract | Monoclonal antibody (mAb) therapy is one of the most promising immunotherapies that have shown the potential to prevent or neutralize the effects of COVID-19 in patients at very early stages, with a few formulations recently approved by the European and American medicine agencies. However, a main bottleneck for their general implementation resides in the time-consuming, laborious, and highly-specialized techniques employed for the manufacturing and assessing of these therapies, excessively increasing their prices and delaying their administration to the patients. We propose a biomimetic nanoplasmonic biosensor as a novel analytical technique for the screening and evaluation of COVID-19 mAb therapies in a simpler, faster, and reliable manner. By creating an artificial cell membrane on the plasmonic sensor surface, our label-free sensing approach enables real-time monitoring of virus-cell interactions as well as direct analysis of antibody blocking effects in only 15 minutes assay time. We have achieved detection limits in the 10² TCID50/mL range for the study of SARS-CoV-2 viruses, which allows to perform neutralization assays by only employing a low-volume sample with common viral loads. We have demonstrated the accuracy of the biosensor for the evaluation of two different neutralizing antibodies targeting both Delta and Omicron variants of SARS-CoV-2, with half maximal inhibitory concentrations (IC₅₀) determined in the ng/mL range. Our user-friendly and reliable technology could be employed in biomedical and pharmaceutical laboratories to accelerate, cheapen, and simplify the development of effective immunotherapies for COVID-19 and other serious infectious diseases or cancer. |
|---|---|
| Keywords | COVID-19 infection ; Severe acute respiratory syndrome coronavirus 2 ; analytical methods ; biomimetics ; biosensors ; cell membranes ; medicine ; monoclonal antibodies ; neutralization ; therapeutics ; Surface plasmon resonance ; COVID-19 ; Immunotherapy ; Neutralization assay ; Supported lipid bilayer ; Label-free analysis |
| Language | English |
| Dates of publication | 2023-0208 |
| Publishing place | Elsevier B.V. |
| Document type | Article ; Online |
| Note | Pre-press version ; Use and reproduction |
| ZDB-ID | 1011023-9 |
| ISSN | 1873-4235 ; 0956-5663 |
| ISSN (online) | 1873-4235 |
| ISSN | 0956-5663 |
| DOI | 10.1016/j.bios.2023.115137 |
| Database | NAL-Catalogue (AGRICOLA) |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 2275: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.